Locally Advanced Gastric Cancer
Conditions
Interventions
1:From the first day of radiotherapy, Capecitabine was administered 600 mg/m2 twice a day (b.i.d.) orally (PO), d1–14, every 21 days, 2 cycles in total.
2:From the first day of radiotherapy, Capecitabine was administered 700 mg/m2 twice a day (b.i.d.) orally (PO), d1–14, every 21 days, 2 cycles in total.
3:From the first day of radiotherapy, Capecitabine was administered 800 mg/m2 twice a day (b.i.d.) orally (PO), d1–14, every 21 days, 2 cycles in total.
4:From the first day of radiotherapy, Capecitabine was administered 850 mg/m2 twice a day (b.i.d.) orally (PO), d1–14, every 21 days, 2 cycles in total.
5:From the first day of radiotherapy, Capecitabine was administered 900 mg/m2 twice a day (b.i.d.) orally (PO), d1–14, every 21 days, 2 cycles in total.
Sponsors
Peking University School of Oncology, Beijing Cancer Hospital & Institute
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. All patients were 18-70 years old, male or female, and enrolled within 3 months of surgery; 2. Postoperative histologically confirmed locally advanced gastric cancer after D2 resection, including T3, T4 and any T, N1-3, M0; 3. Kps>=70, No more than 10% weight loss within past 6 months, life expectancy >12 months and tolerent radiation; 4. No main organ function disable, Leucocyte>= 4000/uL, a neutrophil count>=1500/uL, PLT >=10000/uL, hemoglobin>=10g/dL, CR<=1.0 upper limit of normal, TB<=1.5 upper limit of normal, AST and ALT<=2.5 upper limit of normal, AKP<=5 upper limit of normal; 5. No upper abdominal chest RT history; 6. Patients shoud understand and sign the Informed consent; 7. No history of allergy to 5-fluorouracil.
Exclusion criteria
Exclusion criteria: 1. Patients are receiving other anti-cancer therapy, and pregnant and lactating women; 2. Patients with a second primary tumor other than non-melanoma skin cancer or in situ cervical carcinoma; 3. Any chemotherapy contraindications such as active infection, uncontrolled diabetes, prior allergic reaction to fluorouracil and other serious disease, for example myocardial infarction; 4. Uncontrolable madman psychopath; 5. Investigator consider inappropriate patients for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| response rate, toxicity; | — |
Countries
China
Contacts
Public ContactGuangying Zhu
Outcome results
None listed